Oxidative Stress in IgA Nephropathy

R. Coppo    R. Camilla    A. Amore    L. Peruzzi
Nephrology, Dialysis, Transplantation, Regina Margherita University Hospital, Turin, Italy

Key Words
Advanced oxidation protein products · Chronic kidney disease · IgA nephropathy · Oxidative stress · Pathogenesis of IgAN

Abstract
IgA nephropathy (IgAN) is characterized by mesangial deposits of IgA1, likely due to accumulation of IgA immune complexes. The activation of intracellular signaling mostly results in oxidative stress, as detected in mesangial cells cultured with aberrantly glycosylated IgA or IgA aggregates and in renal biopsies of patients with IgAN. Signs of altered oxidation/antioxidation balance have been detected in sera and/or in erythrocytes of patients with IgAN, including increased levels of lipoperoxide or malondialdehyde and reduced activity of superoxide dismutase, catalase and glutathione peroxidase. Moreover, increased levels of a maker of oxidative stress, advanced oxidation protein products (AOPPs), have been reported to be significantly associated with proteinuria and disease progression in patients with IgAN. AOPPs are often carried by albumin and can in turn enhance the oxidative stress in the circulation. Recent research suggests that the nephrotoxicity of aberrantly glycosylated IgA1 in IgAN is enhanced in the presence of systemic signs of oxidative stress, and it is tempting to hypothesize that the level of the oxidative milieu conditions the different expression and progression of IgAN.

Oxidants in Chronic Kidney Disease

It is known that patients with uremia present with an increase in plasma protein oxidation, including thiol residue oxidation and carbonyl formation together with a de-
crease in important intracellular and circulating antioxidants, of which thiol groups of albumin are quantitatively the most important [3]. Besides uremia, experimental evidence supports the role of oxidants not only in inducing tubulointerstitial damage which accompanies progression, but also in the early stages of glomerular damage [4]. Enhanced generation of oxidants by infiltrating leukocytes has been demonstrated in anti-Thy1.1 and anti-GBM-induced glomerulonephritis, and plays a major role in inducing exudative and proliferative glomerular changes. Leukocytes are thought to cause proteinuria by degrading the glomerular basement membrane activating a latent metalloproteinase by HOCl or a similar oxidant generated by the myeloperoxidase-H2O2-halide system.

Proteinuric experimental models lacking infiltrating leukocytes, like nephrosis induced by injection of puromycin aminonucleoside, have also demonstrated a role of oxidants. The role of oxidative stress in inducing proteinuria is supported by a recent report which detects a causative link between advanced oxidation protein products (AOPPs) and podocyte depletion [5]. AOPPs are a family of oxidized, dityrosine-containing protein-insoluble products, resistant to proteolysis, generated by oxidative stress associated with monocyte activation, myeloperoxidase release, and production of reactive oxygen species. Increased levels of AOPPs are associated with high proteinuria, monocyte interstitial infiltration and glomerulosclerosis in murine models of remnant kidneys. AOPPs activate the intrarenal redox-sensitive pathway with nuclear translocation of nuclear factor κB (NF-κB) and synthesis of pro-inflammatory and pro-sclerotic mediators [6]. AOPPs induce podocyte apoptosis when injected in experimental animals and when incubated in podocyte cultures at remarkably low doses. AOPPs induce intracellular superoxide generation in podocytes by a mechanism involving nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. The cascade of intracellular signaling events finally leads to p53-dependent apoptosis [5]. The conclusion from this recent report suggests that AOPP-mediated apoptosis plays a critical role in promoting proteinuria and accelerating glomerular sclerosis.

**Activation of the Oxidative Stress Pathway in IgAN**

The activation of intracellular signaling mostly results in oxidative stress, as detected in mesangial cells cultured with aberrantly glycosylated IgA or IgA aggregates [7, 8] and in renal biopsies of patients with IgAN, similar to what has been detected in diabetic nephropathy [9]. Signs of altered oxidation/antioxidation balance have been detected in sera and/or in erythrocytes of patients with IgAN, including increased levels of lipoperoxide or malondialdehyde and reduced activity of superoxide dismutase, catalase and glutathione peroxidase [10, 11]. Moreover, increased levels of AOPPs have been recently reported to be significantly associated with proteinuria and disease progression in patients with IgAN [12]. AOPPs are often carried by albumin and can in turn enhance the oxidative stress in the circulation. AOPPs are detected in patients with advanced chronic renal failure, but in IgAN they are independent early predictors of poor renal outcome [12].

**Variable Natural History of IgAN**

One of the most fascinating and still unanswered questions concerning IgAN is the extreme variability of natural history in individual patients, ranging from rapidly progressive cases to ‘lanthanic’ IgA innocent deposits (4–16%; averaging about 70,000 per million population) [13]. It can be debated whether these are ‘innocent’ findings or whether these subjects represent a state of ‘pre-disease’ awaiting another event (a second ‘hit’) to bring the disease to full clinical and recognizable expression. Moreover, the disease can show no sign of progression at all even after decades in 5–50% of patients, or progress to end-stage renal failure within 20 years in 80% of patients.

**New Working Hypothesis on Pathogenesis of Progressive IgAN**

The unique role of circulating aberrantly IgA1 in inducing IgAN renal lesions and the wide spectrum of disease progression has been questioned, as similar IgA1 abnormalities have been described in both familial and sporadic cases of IgAN as well as in healthy first-degree relatives but not in their spouses. In patients with IgAN, individual O-galactosylation patterns of serum IgA1 was reported by Smith and Feehally’s group [13] to remain constant over long periods of time. These were also loosely associated with severity of renal disease, but the overlap between different groups of progressors or non-progressors suggested that altered IgA1 O-glycosylation alone is insufficient to trigger progression.

In a collaborative study among Italian and US researchers, presented at the last IgA Nephropathy Net-
work Meeting in 2009 [13], we showed the concomitant presence in patient sera of aberrantly glycosylated IgA1 and signs of oxidative stress, increased AOPP and decreased free thiol groups of serum albumin. Total levels of aberrantly glycosylated IgA1 resulted in being only weakly associated with clinical activity and progression of renal damage. However, the relative degree of galactose deficiency of IgA1 in association with the concomitant activation of the oxidation pathway resulted in being correlated with proteinuria and informative for disease progression. These data suggest that the nephrotoxicity of aberrantly glycosylated IgA1 in IgAN is enhanced in the presence of systemic signs of oxidative stress.

It is of interest that the increase in AOPP levels in patients with IgAN were reported to be correlated with levels of proteinuria [12] and were detected in patients with preserved renal function, hence suggesting an early activation of the process in IgAN, largely before reaching uremia. It may be speculated that in patients with IgAN, mesangial cells are under the effect not only of deposited aberrantly glycosylated IgA1 but also of circulating and locally generated AOPPs. Both mediators trigger the oxidative stress pathways, notably NF-κB nuclear translocation favoring inflammation and sclerosis [6, 7]. Recently, we also reported that peripheral lymphomonocytes from patients with IgAN have an increased nuclear translocation of this powerful transcription factor, which can support a condition of systemic activation of oxidation [14].

The role of the oxidative milieu as a risk factor for progression of IgAN as well as for mortality has recently also been supported by the association with the polymorphism in the promoter region of the heme oxygenase-1 conditioning the low activity of this system [15]. The support for this hypothesis would be that antioxidant therapy is effective in treating IgAN. The rationale of some therapeutic approaches to IgAN, like fish-oil/omega-3 polyunsaturated fatty acids as well as vitamin E, was based on the aim of downregulating the oxidative status, however, results were not convincing. Like other unfruitful attempts to modulate the oxidoreductive balance in human diseases, it is still debated whether the inconsistent clinical results were affected by inadequate effectiveness of the agents used or by escape mechanisms. However, recent studies indicate that the area is still open to new strategies focusing on the contribution to renal damage induced by oxidative stress pathway activation in IgAN. Genetic control of antioxidant responses may be crucial in individual patients, and studies investigating regulation/augmentation of antioxidant responses seem to be a very promising field of future research.

References

The review by Coppo et al. revisits the pathogenesis of IgA nephropathy, one of the most common causes of glomerulonephritis worldwide. It challenges the hypothesis that abnormal IgA1 O-glycosylation is sufficient on its own to explain the progression of the disease. It suggests very elegantly that in addition to abnormalities of IgA1, oxidant stress (generation of advanced oxidation protein products – AOPPs) is necessary to promote the progression of glomerular damage and CKD. Of interest, a recent report of IgAN after bone marrow transplantation suggests that the pathogenesis of the disease is due to a multi-hit process associated with glomerular deposition of galactose-deficient IgA1. In this report from Boston, two bone marrow transplant recipients provide a unique insight into the kinetics of overproduction of galactose-deficient IgA1 and its glomerular deposition in IgAN [1]. These cases may indirectly lend support to the Coppo hypothesis as her group has recently shown that circulating lymphomonocytes from patients with IgAN have an increased nuclear translocation of NF-κB, a powerful pro-inflammatory transcription factor, which would promote systemic activation of oxidation in IgAN [2]. The story of IgAN may be unravelling as a multi-hit condition with abnormalities of O-glycosylation of IgA1, pro-inflammatory cells as well as generation of pro-inflammatory and pro-sclerotic AOPPs.

References